Neuroblastoma cell line labeled with fluorescent molecules

Neuroblastoma Recurrence Monitoring Method Developed

Using ddPCR, researchers discover expression levels of seven key biomarkers in the bone marrow samples of 17 patients who had suffered tumor relapse and regrowth were significantly higher compared to the levels in the 56 patients who hadn't relapsed.

New Liquid Biopsy Tackles Early Cancer Detection via Cell Clusters

The study presents clinical evidence for an innovative liquid biopsy assay which can detect cell clusters of any type of cancer called C-ETACs (Circulating Ensembles of Tumor Associated Cells) in the blood of asymptomatic individuals.

ProSciento, Nordic Bioscience Partner to Develop Translational Biomarkers for NASH

Companies plan to combine ProSciento’s NASH PASS patient registry with Nordic Bioscience’s Protein FingerPrint technology.
CellMax Life's CMxTM circulating tumor cell (CTC) platform and liquid biopsy panel will be used by Medigen Biotech in upcoming clinical trials of its cell therapy candidates for cancers

New Liquid Biopsy Method IDs Melanoma Patients Likely to Relapse

Although CTCs can be detected in melanoma patients, there is limited data regarding their significance in stage III (node-positive) disease. This prospective study was based on earlier studies that found CTCs in a significant number of breast cancer patients was associated with relapse, independent of other prognostic methods.

Biological Dynamics to Commercialize Biomarker Isolation Tech via Microsoft OCP Program

Biological Dynamics is developing assays for pharmaceutical applications built on Verita, the company’s proprietary biomarker isolation technology that can isolate DNA and extracellular vesicles from plasma and serum without the need to pre-process samples.
Brain tumour, illustration

Imaging Plus Deep Molecular Analysis Improves Precision Cancer Treatment

The research team correlated the genetic and protein fingerprints of brain cancer cells with how those cells and surrounding cells looked using MRI, a test routinely performed as soon as brain cancer is suspected.
Epic Sciences plans to accelerate development of its liquid biopsy cancer tests

Promising Liquid Biopsy for Gastric Cancer Recurrence Developed

The researchers performed deep sequencing of both circulating cfDNA and of white blood cells to look for mutations. Subtracting the white blood cells’ information from cfDNA yielded data investigators could use to predict cancer recurrence within nine weeks following preoperative treatment and surgery.
Results from a new study show the validity of using CSF as a medium for finding ctDNA to detect brain tumors. [Jonathan Bailey

Liquid Biopsy Plus AI Predicts Neurodegenerative Disease Progression

The researchers developed an algorithm that was able to detect how patients’ gene expression patterns changed over decades, offering the first long-term view of molecular changes underlying neurodegeneration.
New research examines why some children born with heart defects also have developmental disabilities. [Image courtesy of Mark L. Riccio

Genes Previously Linked to Heart Condition Disputed

The Clinical Genome Resource's (ClinGen) expert panel has critically reevaluated the scientific evidence for all 17 reported genes, and has concluded at least nine of the genes cannot be linked to the disease, and only three of the genes can be definitively associated with the most common form of the disease.
EEG with electrical activity of abnormal brain, electroencephalogram,EEG

Invitae, BioMarin Expand Screening Program for Genetic Epilepsy

The program’s goal is to identify hereditary diseases that might cause a child’s seizures. Participating companies sponsor the cost of testing using the Invitae Epilepsy Panel, which analyzes more than 180 genes associated with causes of epilepsy and other neurodegenerative conditions.
Scroll Up